$1,330,000 of ABBVIE INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment Issues related to Parkinsons pharmaceutical innovation H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program Issues related to antitrust and competition policy Issues related to pharmaceutical tariffs and unfair trade practices"
You can find more data on corporate lobbying on Quiver Quantitative.
ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 12 times in the past 6 months. Of those trades, 3 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 12/18, 11/13, 08/14.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 5 times. They made 2 purchases worth up to $30,000 on 10/30, 07/22 and 3 sales worth up to $45,000 on 10/31, 10/30, 07/22.
- SENATOR JOHN BOOZMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/22, 08/11.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABBV Insider Trading Activity
ABBV insiders have traded $ABBV stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- AZITA SALEKI-GERHARDT (EVP, CHIEF OPERATIONS OFFICER) sold 42,370 shares for an estimated $8,407,055
- NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) has made 0 purchases and 2 sales selling 13,295 shares for an estimated $2,639,252.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABBV Hedge Fund Activity
We have seen 1,863 institutional investors add shares of ABBV stock to their portfolio, and 1,592 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 10,559,645 shares (+72.3%) to their portfolio in Q3 2025, for an estimated $2,444,980,203
- WELLINGTON MANAGEMENT GROUP LLP added 8,646,424 shares (+457.4%) to their portfolio in Q3 2025, for an estimated $2,001,993,012
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 3,134,454 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $725,751,479
- CAPITAL INTERNATIONAL INVESTORS removed 2,947,890 shares (-21.6%) from their portfolio in Q3 2025, for an estimated $682,554,450
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,830,775 shares (-53.6%) from their portfolio in Q3 2025, for an estimated $423,897,643
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 1,771,612 shares (+37.5%) to their portfolio in Q3 2025, for an estimated $410,199,042
- ALLIANCEBERNSTEIN L.P. added 1,758,657 shares (+31.8%) to their portfolio in Q3 2025, for an estimated $407,199,441
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ABBV Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 12/10/2025
- Guggenheim issued a "Buy" rating on 10/20/2025
- Piper Sandler issued a "Overweight" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/15/2025
- BMO Capital issued a "Outperform" rating on 09/12/2025
To track analyst ratings and price targets for ABBV, check out Quiver Quantitative's $ABBV forecast page.
ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 16 analysts offer price targets for $ABBV in the last 6 months, with a median target of $250.5.
Here are some recent targets:
- Michael Yee from UBS set a target price of $240.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $269.0 on 12/12/2025
- Rajesh Kumar from HSBC set a target price of $265.0 on 12/10/2025
- David Amsellem from Piper Sandler set a target price of $289.0 on 11/05/2025
- Geoff Meacham from Citigroup set a target price of $235.0 on 11/03/2025
- Chris Schott from JP Morgan set a target price of $260.0 on 11/03/2025
- Vamil Divan from Guggenheim set a target price of $242.0 on 10/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
